Indinavir (Crixivan)

06/01/2007 - "Due to its low cost and proven efficacy indinavir remains a key component of HIV/AIDS treatment in resource-limited settings."
01/01/2009 - "Indinavir-loaded pH-sensitive microparticles for taste masking: toward extemporaneous pediatric anti-HIV/AIDS liquid formulations with improved patient compliance."
01/01/2000 - "A randomized double-blind study to evaluate the efficacy of indinavir alone (800 mg q8h), zidovidine alone (200 mg q8h) or the combination was performed to evaluate progression to AIDS. "
09/01/2002 - "The 24-week extension of AIDS Clinical Trials Group Protocol 359, a study of human immunodeficiency virus (HIV)-infected, indinavir-experienced patients, was designed to study the durability of "salvage" treatment regimens. "
01/01/2014 - "Persons with diabetes had increased odds of PTU, as were those with a prior non-AIDS (1) or AIDS event and those with prior exposure to indinavir. "

03/18/2011 - "In conclusion, pegylated SLEs improved brain specific delivery of indinavir and will be useful in treating chronic HIV infection."
12/01/1999 - "Numerous additional clinical trials have established the beneficial antiviral and immunological effects of indinavir in both antiretroviral-naive and -experienced patients with HIV infection. "
12/01/2003 - "Collectively, these data indicate that lipid association greatly enhances delivery of the anti-HIV drug indinavir to lymph nodes at levels that cannot be achieved with soluble drug, provides significant virus load reduction, and could potentially reverse CD4 T cell depletion due to HIV infection."
05/04/2001 - "Indinavir 800 mg twice daily was given to 10 HIV-seronegative healthy men to distinguish direct metabolic effects of a PI from those related to HIV infection. "
11/01/2000 - "Indinavir is an antiviral agent used for the treatment of HIV infection. "

12/01/1999 - "Indinavir therapy has demonstrated promise in the treatment of HIV-1 infection in clinical trials; however, its efficacy in a U.S. "
09/11/1997 - "A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. "
09/01/2011 - "There is much evidence to indicate the ability of Indinavir (IND) to reduce Cryptosporidium parvum infection in both in vitro and in vivo models. "
10/01/2004 - "Furthermore, as assessed by an in vitro infection model, indinavir significantly and consistently augmented C. "
06/01/2004 - "For established infection, indinavir treatment reduced the number of oocysts in the entire intestinal content by about 50% and the number of intracellular parasites in the ileum by about 70%. "

06/01/1999 - "Indinavir-induced lipodystrophy constitutes a new complication of this therapeutic category. "
02/11/1999 - "[Indinavir-associated lipodystrophy]."
01/01/1999 - "In conclusion, facial lipodystrophy is a common occurrence among patients receiving indinavir, and physicians should be alerted to this condition."
01/01/1999 - "Facial lipodystrophy was not observed in patients who had received indinavir for less than 3 months. "
01/01/1999 - "Among 29 patients who had been receiving indinavir for 3 months or more, facial lipodystrophy was found in 7 (24%). "

04/15/2002 - "The objective of the present study was to characterize the genitourinary syndromes that accompany indinavir-associated pyuria. "
04/15/2002 - "Pyuria continued in the 3 patients who continued receiving indinavir. "
10/01/2000 - "In 21 patients, among them 11 with pyuria, indinavir was replaced for various reasons and pyuria disappeared in nine. "
10/01/2000 - "Pyuria in patients treated with indinavir is associated with renal dysfunction."
02/01/1999 - "Sterile pyuria in patients taking indinavir may help to identify patients at risk for renal dysfunction and interstitial nephritis. "